Development of the RapidMist™ drug delivery system for the treatment of diabetes, cardiovascular diseases and breakthrough cancer pain

The current advocacy of intensive diabetes therapy regimens involving multiple daily injections places a heavy burden of compliance on patients and has prompted interest in developing alternative, less invasive routes of delivery. Among alternative methods for administering insulin, Generex Biotechnology has developed the RapidMist (TM) Diabetes Management System. The technology allows a liquid aerosolized formulation of insulin (Oral-lyn (TM), formerly Oralin (TM)) to be delivered accurately into the mouth of the patient via a spray. This novel pain-free delivery system has several important attributes: rapid absorption, a user-friendly administration technique, precise dosing control (comparable to injection within 1 U) and bolus delivery of drug. Several studies conducted in subjects with type 1 and type 2 diabetes demonstrated clearly that Oral-lyn (TM) provides metabolic control comparable to s.c. injections of insulin. The simplified means of pain-free prandial insulin delivery offered by this technique will significantly reduce the incidence of major complications by increasing patient compliance, resulting in the consistent drug administration necessary to regulate blood glucose levels.